{"title":"[新型冠状病毒感染对多发性骨髓瘤患者自体外周血干细胞动员和采集的影响]。","authors":"Guo-Rong Wang, Guang-Zhong Yang, Yun Leng, Yin Wu, Ai-Jun Liu, Wen-Ming Chen","doi":"10.19746/j.cnki.issn.1009-2137.2025.02.021","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>To analyze the effect of COVID-19 infection on the mobilization and collection of autologous peripheral blood stem cells in patients with multiple myeloma.</p><p><strong>Methods: </strong>The general baseline data, treatment factors before mobilization collection, collection status, and treatment overview after collection of autologous peripheral blood stem cells at Beijing Chaoyang Hospital affiliated with Capital Medical University from January 1, 2020 to July 15, 2023 were analyzed.</p><p><strong>Results: </strong>269 patients underwent mobilization and collection of autologous peripheral blood stem cells. Among them, 32 cases with COVID-19 infection history (COVID-19 group) and 237 cases without COVID-19 infection history (non-COVID-19 group). In the COVID-19 group, 17 cases were treated with chemotherapy (etoposide)+G-CSF, and 15 cases were treated with plerixafor +G-CSF. In the non-COVID-19 group, 214 cases were treated with chemotherapy +G-CSF, 17 cases were treated with plerixafor +G-CSF, and 6 cases were treated with chemotherapy + plerixafor +G-CSF. The number of CD34<sup>+</sup> cells, collection success rate, and excellence rate in the COVID-19 group and the non-COVID-19 group were ［5.52 (0.94-26.87) <i>vs</i> 4.80 (0.53-37.20)］×10<sup>6</sup>/kg (<i>P</i> =0.610), (93.8% <i>vs</i> 85.2%) (<i>P</i> =0.275), (62.5% <i>vs</i> 49.4%) (<i>P</i> =0.190), respectively. Among 113 patients mobilized with etoposide +G-CSF, the number of CD34<sup>+</sup> cells, success rate, and excellence rate collected from COVID-19 infection (17 cases) and non-COVID-19 infection (96 cases) were ［7.54 (2.66-26.87) <i>vs</i> 7.78 (2.26-37.20)］×10<sup>6</sup>/kg (<i>P</i> =0.847), (100.0% <i>vs</i> 100.0%) (no <i>P</i> value), (82.4% <i>vs</i> 86.5%) (<i>P</i> =0.655), respectively. Among 32 patients mobilized by plerixafor +G-CSF, the number of CD34<sup>+</sup> cells, success rate and excellence rate of COVID-19 infection (15 cases) and non-COVID-19 infection (17 cases) were ［3.82 (0.94-7.27) <i>vs</i> 4.11 (0.53-9.05)］×10<sup>6</sup>/kg (<i>P</i> =0.821), (86.7% <i>vs</i> 88.2%) (<i>P</i> =0.893), (40.0% <i>vs</i> 35.3%) (<i>P</i> =0.784), respectively. In 32 patients with COVID-19 infection, the number of CD34<sup>+</sup> cells collected by etoposide +G-CSF (17 cases) and plerixafor +G-CSF (15 cases), as well as the success rate and excellence rate were ［7.54 (2.66-26.87) <i>vs</i> 3.82(0.94-7.27)］×10<sup>6</sup>/kg (<i>P</i> =0.004), (100.0% <i>vs</i> 86.7%) (<i>P</i> =0.120), (82.4% <i>vs</i> 40.0%) (<i>P</i> =0.014), respectively. By 2023.7.31, 232 patients (86.2%, 232/269) had received transplantation, including 24 patients in the COVID-19 group and 208 patients in the non-COVID-19 group. The median number of CD34<sup>+</sup> cells infused in the two groups was ［3.67 (2.50-13.44) <i>vs</i> 3.11(1.12-19.89)］×10<sup>6</sup>/kg (<i>P</i> =0.058), the median days of neutrophil engraftment ［11(9-13) <i>vs</i> 11(9-17)］ (<i>P</i> =0.674), the median days of platelet engraftment ［11(0-23), 12(0-43)］ (<i>P</i> =0.279), respectively.</p><p><strong>Conclusion: </strong>The history of COVID-19 infection did not affect the PBSC mobilization, collection and transplantation of patients with myeloma. In patients with COVID-19 infection, the results of chemotherapy mobilization with etoposide seems to be better than that of plerixafor mobilization, but further research is needed to clarify.</p>","PeriodicalId":35777,"journal":{"name":"中国实验血液学杂志","volume":"33 2","pages":"455-462"},"PeriodicalIF":0.0000,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"[The Influence of COVID-19 Infection on the Mobilization and Collection of Autologous Peripheral Blood Stem Cells in Patients with Multiple Myeloma].\",\"authors\":\"Guo-Rong Wang, Guang-Zhong Yang, Yun Leng, Yin Wu, Ai-Jun Liu, Wen-Ming Chen\",\"doi\":\"10.19746/j.cnki.issn.1009-2137.2025.02.021\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Objective: </strong>To analyze the effect of COVID-19 infection on the mobilization and collection of autologous peripheral blood stem cells in patients with multiple myeloma.</p><p><strong>Methods: </strong>The general baseline data, treatment factors before mobilization collection, collection status, and treatment overview after collection of autologous peripheral blood stem cells at Beijing Chaoyang Hospital affiliated with Capital Medical University from January 1, 2020 to July 15, 2023 were analyzed.</p><p><strong>Results: </strong>269 patients underwent mobilization and collection of autologous peripheral blood stem cells. Among them, 32 cases with COVID-19 infection history (COVID-19 group) and 237 cases without COVID-19 infection history (non-COVID-19 group). In the COVID-19 group, 17 cases were treated with chemotherapy (etoposide)+G-CSF, and 15 cases were treated with plerixafor +G-CSF. In the non-COVID-19 group, 214 cases were treated with chemotherapy +G-CSF, 17 cases were treated with plerixafor +G-CSF, and 6 cases were treated with chemotherapy + plerixafor +G-CSF. The number of CD34<sup>+</sup> cells, collection success rate, and excellence rate in the COVID-19 group and the non-COVID-19 group were ［5.52 (0.94-26.87) <i>vs</i> 4.80 (0.53-37.20)］×10<sup>6</sup>/kg (<i>P</i> =0.610), (93.8% <i>vs</i> 85.2%) (<i>P</i> =0.275), (62.5% <i>vs</i> 49.4%) (<i>P</i> =0.190), respectively. Among 113 patients mobilized with etoposide +G-CSF, the number of CD34<sup>+</sup> cells, success rate, and excellence rate collected from COVID-19 infection (17 cases) and non-COVID-19 infection (96 cases) were ［7.54 (2.66-26.87) <i>vs</i> 7.78 (2.26-37.20)］×10<sup>6</sup>/kg (<i>P</i> =0.847), (100.0% <i>vs</i> 100.0%) (no <i>P</i> value), (82.4% <i>vs</i> 86.5%) (<i>P</i> =0.655), respectively. Among 32 patients mobilized by plerixafor +G-CSF, the number of CD34<sup>+</sup> cells, success rate and excellence rate of COVID-19 infection (15 cases) and non-COVID-19 infection (17 cases) were ［3.82 (0.94-7.27) <i>vs</i> 4.11 (0.53-9.05)］×10<sup>6</sup>/kg (<i>P</i> =0.821), (86.7% <i>vs</i> 88.2%) (<i>P</i> =0.893), (40.0% <i>vs</i> 35.3%) (<i>P</i> =0.784), respectively. In 32 patients with COVID-19 infection, the number of CD34<sup>+</sup> cells collected by etoposide +G-CSF (17 cases) and plerixafor +G-CSF (15 cases), as well as the success rate and excellence rate were ［7.54 (2.66-26.87) <i>vs</i> 3.82(0.94-7.27)］×10<sup>6</sup>/kg (<i>P</i> =0.004), (100.0% <i>vs</i> 86.7%) (<i>P</i> =0.120), (82.4% <i>vs</i> 40.0%) (<i>P</i> =0.014), respectively. By 2023.7.31, 232 patients (86.2%, 232/269) had received transplantation, including 24 patients in the COVID-19 group and 208 patients in the non-COVID-19 group. The median number of CD34<sup>+</sup> cells infused in the two groups was ［3.67 (2.50-13.44) <i>vs</i> 3.11(1.12-19.89)］×10<sup>6</sup>/kg (<i>P</i> =0.058), the median days of neutrophil engraftment ［11(9-13) <i>vs</i> 11(9-17)］ (<i>P</i> =0.674), the median days of platelet engraftment ［11(0-23), 12(0-43)］ (<i>P</i> =0.279), respectively.</p><p><strong>Conclusion: </strong>The history of COVID-19 infection did not affect the PBSC mobilization, collection and transplantation of patients with myeloma. In patients with COVID-19 infection, the results of chemotherapy mobilization with etoposide seems to be better than that of plerixafor mobilization, but further research is needed to clarify.</p>\",\"PeriodicalId\":35777,\"journal\":{\"name\":\"中国实验血液学杂志\",\"volume\":\"33 2\",\"pages\":\"455-462\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2025-04-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"中国实验血液学杂志\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.19746/j.cnki.issn.1009-2137.2025.02.021\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"中国实验血液学杂志","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.19746/j.cnki.issn.1009-2137.2025.02.021","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0
摘要
目的：分析新型冠状病毒感染对多发性骨髓瘤患者自体外周血干细胞动员和采集的影响。方法：分析2020年1月1日至2023年7月15日首都医科大学附属北京朝阳医院自体外周血干细胞采集的一般基线资料、动员采集前的治疗因素、采集情况及采集后的治疗概况。结果：269例患者接受了自体外周血干细胞的动员和采集。其中有COVID-19感染史32例（COVID-19组），无COVID-19感染史237例（非COVID-19组）。新冠肺炎组化疗（依托泊苷）+G-CSF 17例，普利沙韦+G-CSF 15例。非covid -19组化疗+G-CSF 214例，普利沙福+G-CSF 17例，化疗+普利沙福+G-CSF 6例。COVID-19组和非COVID-19组CD34+细胞数、收集成功率和优秀率分别为[5.52 (0.94-26.87)vs 4.80 (0.53-37.20)]×106/kg （P =0.610）、（93.8% vs 85.2%） （P =0.275）、（62.5% vs 49.4%） （P =0.190）。在113例使用etopo苷+G-CSF动员的患者中，COVID-19感染（17例）和非COVID-19感染（96例）采集的CD34+细胞数、成功率和优优率分别为[7.54 (2.66-26.87)vs 7.78 (2.26-37.20)]×106/kg （P =0.847）、（100.0% vs 100.0%）（无P值）、（82.4% vs 86.5%） （P =0.655）。在32例使用plerixafor +G-CSF的患者中，CD34+细胞数、COVID-19感染（15例）和非COVID-19感染（17例）的成功率和显效率分别为[3.82 (0.94-7.27)vs 4.11 (0.53-9.05)]×106/kg （P =0.821）、（86.7% vs 88.2%） （P =0.893）、（40.0% vs 35.3%） （P =0.784）。在32例COVID-19感染患者中，etopo苷+G-CSF（17例）和plerixafor +G-CSF（15例）采集的CD34+细胞数量和成功率分别为[7.54 (2.66-26.87)vs 3.82(0.94-7.27)]×106/kg （P =0.004）、（100.0% vs 86.7%） （P =0.120）、（82.4% vs 40.0%） （P =0.014）。截至2023.7.31，共有232例（86.2%,232/269）患者接受了移植，其中COVID-19组24例，非COVID-19组208例。两组CD34+细胞输注的中位数分别为[3.67 (2.50-13.44)vs 3.11(1.12-19.89)]×106/kg (P =0.058)，中性粒细胞移植的中位数天数[11(9-13)vs 11(9-17)] (P =0.674)，血小板移植的中位数天数[11(0-23),12(0-43)]（P =0.279）。结论：COVID-19感染史对骨髓瘤患者外周血细胞动员、采集和移植无影响。在COVID-19感染患者中，依托泊苷的化疗动员效果似乎优于普立沙的动员效果，但需要进一步的研究来阐明。
[The Influence of COVID-19 Infection on the Mobilization and Collection of Autologous Peripheral Blood Stem Cells in Patients with Multiple Myeloma].
Objective: To analyze the effect of COVID-19 infection on the mobilization and collection of autologous peripheral blood stem cells in patients with multiple myeloma.
Methods: The general baseline data, treatment factors before mobilization collection, collection status, and treatment overview after collection of autologous peripheral blood stem cells at Beijing Chaoyang Hospital affiliated with Capital Medical University from January 1, 2020 to July 15, 2023 were analyzed.
Results: 269 patients underwent mobilization and collection of autologous peripheral blood stem cells. Among them, 32 cases with COVID-19 infection history (COVID-19 group) and 237 cases without COVID-19 infection history (non-COVID-19 group). In the COVID-19 group, 17 cases were treated with chemotherapy (etoposide)+G-CSF, and 15 cases were treated with plerixafor +G-CSF. In the non-COVID-19 group, 214 cases were treated with chemotherapy +G-CSF, 17 cases were treated with plerixafor +G-CSF, and 6 cases were treated with chemotherapy + plerixafor +G-CSF. The number of CD34+ cells, collection success rate, and excellence rate in the COVID-19 group and the non-COVID-19 group were ［5.52 (0.94-26.87) vs 4.80 (0.53-37.20)］×106/kg (P =0.610), (93.8% vs 85.2%) (P =0.275), (62.5% vs 49.4%) (P =0.190), respectively. Among 113 patients mobilized with etoposide +G-CSF, the number of CD34+ cells, success rate, and excellence rate collected from COVID-19 infection (17 cases) and non-COVID-19 infection (96 cases) were ［7.54 (2.66-26.87) vs 7.78 (2.26-37.20)］×106/kg (P =0.847), (100.0% vs 100.0%) (no P value), (82.4% vs 86.5%) (P =0.655), respectively. Among 32 patients mobilized by plerixafor +G-CSF, the number of CD34+ cells, success rate and excellence rate of COVID-19 infection (15 cases) and non-COVID-19 infection (17 cases) were ［3.82 (0.94-7.27) vs 4.11 (0.53-9.05)］×106/kg (P =0.821), (86.7% vs 88.2%) (P =0.893), (40.0% vs 35.3%) (P =0.784), respectively. In 32 patients with COVID-19 infection, the number of CD34+ cells collected by etoposide +G-CSF (17 cases) and plerixafor +G-CSF (15 cases), as well as the success rate and excellence rate were ［7.54 (2.66-26.87) vs 3.82(0.94-7.27)］×106/kg (P =0.004), (100.0% vs 86.7%) (P =0.120), (82.4% vs 40.0%) (P =0.014), respectively. By 2023.7.31, 232 patients (86.2%, 232/269) had received transplantation, including 24 patients in the COVID-19 group and 208 patients in the non-COVID-19 group. The median number of CD34+ cells infused in the two groups was ［3.67 (2.50-13.44) vs 3.11(1.12-19.89)］×106/kg (P =0.058), the median days of neutrophil engraftment ［11(9-13) vs 11(9-17)］ (P =0.674), the median days of platelet engraftment ［11(0-23), 12(0-43)］ (P =0.279), respectively.
Conclusion: The history of COVID-19 infection did not affect the PBSC mobilization, collection and transplantation of patients with myeloma. In patients with COVID-19 infection, the results of chemotherapy mobilization with etoposide seems to be better than that of plerixafor mobilization, but further research is needed to clarify.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
